ClinicalTrials.gg
CompletedNCT00829166EMILIAUpdated Oct 31, 2016Results posted

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

A Phase 3 interventional study of Trastuzumab emtansine and Lapatinib in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 324 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
991
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Enrollment
7th of 56
991 · median 103
Started
2009
with 5 others
Phase 3
10 of 56
none open now
Registered
4th of 56
by date
Lead sponsor
18 of 56
Hoffmann-La Roche

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 6 that started in 2009, is one of 10 in phase 3, and was the 4th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • (ECOG) performance status of 0 or 1
  • For women of and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of ; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute (NCI-CTCAE), Version 3.0
  • History of other within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed -positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including , to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with (HIV), virus, or virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
991 participants (actual)

Study arms

  • Experimental
    Trastuzumab emtansine

    Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.

    Drug: Trastuzumab emtansine

  • Active comparator
    Lapatinib + Capecitabine

    Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.

    Drug: Lapatinib · Drug: Capecitabine

Interventions

  • DrugAdo-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.

    Also known as: T-DM1, Trastuzumab-MCC-DM1, RO5304020

  • Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.

    Also known as: Tykerb, Tyverb

  • Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.

    Also known as: Xeloda

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)

    PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (\>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  2. Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)

    Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: \>/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  3. Percentage of Participants Who Died: Second Interim Analysis

    The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.

    Time frame: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)

  4. Overall Survival: Second Interim Analysis (Co-primary Endpoint)

    OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.

    Time frame: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)

  5. Percentage of Participants Who Died: Final Analysis

    The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.

    Time frame: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)

  6. Overall Survival: Final Analysis

    OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.

    Time frame: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)

  7. Percentage of Participants Who Were Alive at Year 1

    1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.

    Time frame: Year 1

  8. Percentage of Participants Who Were Alive at Year 2

    2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.

    Time frame: Year 2

Secondary outcomes

  1. Percentage of Participants With PD or Death as Assessed by the Investigator

    PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  2. PFS as Assessed by the Investigator

    Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  3. Percentage of Participants With Objective Response (OR) as Assessed by an IRC

    Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as \>/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  4. Duration of Objective Response (DOR) as Assessed by an IRC

    Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as \>/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  5. Percentage of Participants With Clinical Benefit as Assessed by an IRC

    Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments \>/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: \>/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  6. Percentage of Participants With Treatment Failure

    Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  7. Time to Treatment Failure

    Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  8. Percentage of Participants With Symptom Progression

    Symptom progression was defined as the documentation of a \>/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale \[BCS\]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

  9. Time to Symptom Progression

    Time to symptom progression was defined as the time from randomization to the first documentation of a \>/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.

    Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

07

Results

Posted Apr 23, 2013

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab EmtansineLapatinib + Capecitabine
Started495496
Treated490488
Completed00
Not completed495496
Withdrew: Death305333
Withdrew: Lost to follow-up54
Withdrew: Physician's decision43
Withdrew: Subject's decision4155
Withdrew: Sponsor's decision13798
Withdrew: Reason not specified33

Outcome measures

PrimaryPercentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)

PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (\>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)53.561.3
PrimaryProgression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)

Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: \>/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)9.6 (8.25 to 10.64)6.4 (5.68 to 7.06)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.650 · 95% CI 0.549 to 0.771HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.
PrimaryPercentage of Participants Who Died: Second Interim Analysis

The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.

Time frame:
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died: Second Interim Analysis
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants Who Died: Second Interim Analysis30.136.7
PrimaryOverall Survival: Second Interim Analysis (Co-primary Endpoint)

OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.

Time frame:
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Reported as:
Median · Months
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
Overall Survival: Second Interim Analysis (Co-primary Endpoint)30.9 (26.81 to 34.27)25.1 (22.74 to 27.96)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Log Rank · p = 0.0006 · Hazard ratio (hr): 0.682 · 95% CI 0.548 to 0.849HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.
PrimaryPercentage of Participants Who Died: Final Analysis

The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.

Time frame:
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died: Final Analysis
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants Who Died: Final Analysis61.267.1
PrimaryOverall Survival: Final Analysis

OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.

Time frame:
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Reported as:
Median · Months
Overall Survival: Final Analysis
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
Overall Survival: Final Analysis29.9 (26.32 to 34.10)25.9 (22.74 to 28.32)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Log Rank · p = 0.0003 · Hazard ratio (hr): 0.749 · 95% CI 0.639 to 0.877HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.
PrimaryPercentage of Participants Who Were Alive at Year 1

1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.

Time frame:
Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Alive at Year 1
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants Who Were Alive at Year 185.3 (82.15 to 88.54)78.9 (75.19 to 82.65)
PrimaryPercentage of Participants Who Were Alive at Year 2

2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.

Time frame:
Year 2
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Alive at Year 2
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants Who Were Alive at Year 259.6 (55.10 to 64.06)52.4 (47.81 to 57.08)
SecondaryPercentage of Participants With PD or Death as Assessed by the Investigator

PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD or Death as Assessed by the Investigator
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants With PD or Death as Assessed by the Investigator58.067.5
SecondaryPFS as Assessed by the Investigator

Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Median · Months
PFS as Assessed by the Investigator
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
PFS as Assessed by the Investigator9.4 (7.49 to 10.78)5.8 (5.59 to 6.93)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.658 · 95% CI 0.560 to 0.774HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.
SecondaryPercentage of Participants With Objective Response (OR) as Assessed by an IRC

Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as \>/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants With Objective Response (OR) as Assessed by an IRC43.6 (38.6 to 48.6)30.8 (26.3 to 35.7)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Mantel-Haenszel chi-squared test · p = 0.0002 · Difference in objective response rates: 12.7 · 95% CI 6.0 to 19.4The 95% CI for the difference in objective response rate (Trastuzumab emtansine minus Lapatinib + Capecitabine) was computed by using the approximate normal method.
SecondaryDuration of Objective Response (DOR) as Assessed by an IRC

Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as \>/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Median · Months
Duration of Objective Response (DOR) as Assessed by an IRC
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
Duration of Objective Response (DOR) as Assessed by an IRC12.6 (8.38 to 20.76)6.5 (5.45 to 7.16)
SecondaryPercentage of Participants With Clinical Benefit as Assessed by an IRC

Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments \>/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: \>/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit as Assessed by an IRC
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants With Clinical Benefit as Assessed by an IRC58.2 (53.3 to 63.1)44.2 (39.2 to 49.2)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Difference in clinical benefit rate: 14 · 95% CI 7.0 to 20.9The 95% CI for the difference in clinical benefit rate (Trastuzumab emtansine minus Lapatinib + Capecitabine) was computed by using the normal approximation method.
SecondaryPercentage of Participants With Treatment Failure

Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Failure
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants With Treatment Failure63.274.8
SecondaryTime to Treatment Failure

Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as \>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Median · Months
Time to Treatment Failure
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
Time to Treatment Failure7.9 (6.41 to 9.00)5.8 (5.52 to 6.31)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.703 · 95% CI 0.602 to 0.820HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.
SecondaryPercentage of Participants With Symptom Progression

Symptom progression was defined as the documentation of a \>/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale \[BCS\]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Symptom Progression
percentage of participantsTrastuzumab EmtansineLapatinib + Capecitabine
Percentage of Participants With Symptom Progression54.757.8
SecondaryTime to Symptom Progression

Time to symptom progression was defined as the time from randomization to the first documentation of a \>/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.

Time frame:
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Reported as:
Median · Months
Time to Symptom Progression
MonthsTrastuzumab EmtansineLapatinib + Capecitabine
Time to Symptom Progression7.1 (5.59 to 8.44)4.6 (4.14 to 5.78)
Statistical analysis
  • Trastuzumab Emtansine vs Lapatinib + Capecitabine · Log Rank · p = 0.0121 · Hazard ratio (hr): 0.796 · 95% CI 0.667 to 0.951HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.

Adverse events

Collected over Only study-related serious adverse events (SAEs) were reported from randomization to first treatment; all SAEs and non-SAEs were reported from start of treatment until 30 days after treatment; and thereafter only treatment related SAEs were reported until data cut-off date of 21-Sep-2015 (up to 6 years and 7 months). For participants who crossed over from lapatinib + capecitabine to trastuzumab emtansine, data is reported from time of cross-over until 21-Sep-2015 (up to 3 years and 2 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Emtansine—92/490 (18.8%)474/490 (96.7%)
Lapatinib + Capecitabine—99/488 (20.3%)471/488 (96.5%)
Lapatinib + Capecitabine/ Trastuzumab Emtansine—19/136 (14%)115/136 (84.6%)
Most frequent serious events
Showing 10 of 169
Most frequent serious events
EventTrastuzumab EmtansineLapatinib + CapecitabineLapatinib + Capecitabine/ Trastuzumab Emtansine
DiarrhoeaGastrointestinal disorders3/49017/4880/136
VomitingGastrointestinal disorders7/49010/4880/136
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/4909/4880/136
PyrexiaGeneral disorders8/4903/4882/136
Respiratory tract infectionInfections and infestations0/4900/4882/136
ThrombocytopeniaBlood and lymphatic system disorders4/4901/4881/136
Abdominal painGastrointestinal disorders4/4903/4880/136
PneumoniaInfections and infestations4/4901/4881/136
Macular holeEye disorders0/4900/4881/136
AscitesGastrointestinal disorders0/4900/4881/136
Most frequent other events
Showing 10 of 70
Most frequent other events
EventTrastuzumab EmtansineLapatinib + CapecitabineLapatinib + Capecitabine/ Trastuzumab Emtansine
DiarrhoeaGastrointestinal disorders123/490385/48820/136
Palmar-Plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders7/490291/4887/136
NauseaGastrointestinal disorders202/490224/48835/136
FatigueGeneral disorders180/490145/48830/136
ThrombocytopeniaBlood and lymphatic system disorders150/49013/48823/136
HeadacheNervous system disorders146/49077/48828/136
VomitingGastrointestinal disorders98/490145/48813/136
ConstipationGastrointestinal disorders139/49059/48822/136
RashSkin and subcutaneous tissue disorders64/490133/48817/136
EpistaxisRespiratory, thoracic and mediastinal disorders121/49044/48835/136

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants on the basis of the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)Trastuzumab EmtansineLapatinib + CapecitabineTotal
Mean52.2 ± 11.053.2 ± 10.852.7 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab EmtansineLapatinib + CapecitabineTotal
Female494492986
Male145
08

Study locations

324 sites
  • Chandler, Arizona 85224, United States
  • Tucson, Arizona 85719, United States
  • Anaheim, California 92801, United States
  • Anaheim, California 92807, United States
  • Bakersfield, California 93309, United States
  • Baldwin Park, California 91706, United States
  • Bellflower, California 90706, United States
  • Duarte, California 91010, United States
  • Fontana, California 92335, United States
  • Hayward, California 94545, United States
  • Irvine, California 92618, United States
  • La Jolla, California 92093, United States
  • La Mesa, California 91942, United States
  • Loma Linda, California 92354, United States
  • Long Beach, California 90806, United States
  • Los Angeles, California 90025, United States
  • Los Angeles, California 90034, United States
  • Los Angeles, California 90057, United States
  • Los Angeles, California 90095-1772, United States
  • Montebello, California 90640, United States
  • Newport Beach, California 92660, United States
  • Oakland, California 94611, United States
  • Panorama City, California 91402, United States
  • Riverside, California 92505, United States
  • Roseville, California 95661, United States
  • Sacramento, California 95825, United States
  • San Diego, California 92120, United States
  • San Diego, California 92123, United States
  • San Francisco, California 94115, United States
  • San Jose, California 95119, United States
  • Santa Clara, California 95051, United States
  • Santa Maria, California 93454, United States
  • Santa Monica, California 90404, United States
  • South San Francisco, California 94080, United States
  • Thousand Oaks, California 91360, United States
  • Vallejo, California 94589, United States
  • Walnut Creek, California 94596, United States
  • Woodland Hills, California 91367, United States
  • Fort Collins, Colorado 80528, United States
  • Norwalk, Connecticut 06856, United States
  • Norwich, Connecticut 06360, United States
  • Stamford, Connecticut 06902, United States
  • Washington, District of Columbia 20010, United States
  • Boca Raton, Florida 33486, United States
  • Fernandina Beach, Florida 32034, United States
  • Fort Myers, Florida 33916, United States
  • Ft. Lauderdale, Florida 33316, United States
  • Hollywood, Florida 33021, United States
  • Jacksonville, Florida 32205, United States
  • Jacksonville, Florida 32207, United States
  • Jacksonville, Florida 32256, United States
  • Jacksonville, Florida 32258, United States
  • Kissimmee, Florida 34741, United States
  • Lakeland, Florida 33804-1057, United States
  • Miami, Florida 33133, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33176, United States
  • Orange Park, Florida 32073, United States
  • Pembroke Pines, Florida 33028, United States
  • Athens, Georgia 30607, United States
  • Atlanta, Georgia 30318, United States
  • Atlanta, Georgia 30322, United States
  • Atlanta, Georgia 30341, United States
  • Atlanta, Georgia 30342, United States
  • Carrolton, Georgia 30117, United States
  • Cartersville, Georgia 30121, United States
  • Decatur, Georgia 30033, United States
  • Douglasville, Georgia 30134, United States
  • Macon, Georgia 31217, United States
  • Marietta, Georgia 30060, United States
  • Boise, Idaho 83712, United States
  • Meridian, Idaho 83642, United States
  • Nampa, Idaho 83686, United States
  • Post Falls, Idaho 83854, United States
  • Twin Falls, Idaho 83301, United States
  • Chicago, Illinois 60612, United States
  • Decatur, Illinois 62526, United States
  • Effingham, Illinois 62526, United States
  • Joliet, Illinois 60435, United States
  • Morris, Illinois 60450, United States
  • Peoria, Illinois 61615-7828, United States
  • Skokie, Illinois 60076, United States
  • Zion, Illinois 60099, United States
  • Bettendorf, Iowa 52722, United States
  • Wichita, Kansas 67214-3728, United States
  • Paducah, Kentucky 42001, United States
  • Covington, Louisiana 70433, United States
  • Lafayette, Louisiana 70503, United States
  • Marrero, Louisiana 70072, United States
  • Metairie, Louisiana 70006, United States
  • New Orleans, Louisiana 70115, United States
  • Kittery, Maine 03904, United States
  • Wells, Maine 04090, United States
  • York, Maine 03909, United States
  • Baltimore, Maryland 21202, United States
  • Baltimore, Maryland 21237, United States
  • Bethesda, Maryland 20817, United States
  • Rockville, Maryland 20850, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02115, United States

Showing the first 100 of 324 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dieras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Erratum In: Lancet Oncol. 2017 Aug;18(8):e433. doi: 10.1016/S1470-2045(17)30527-2. Lancet Oncol. 2018 Dec;19(12):e667. doi: 10.1016/S1470-2045(18)30848-9. PubMed 28526536 ↗
  • Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum In: N Engl J Med. 2013 Jun 20;368(25):2442. PubMed 23020162 ↗
  • Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236. PubMed 22437872 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Jul 2012 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2009
First posted
Jan 26, 2009
Start
Feb 2009
Primary completionActual
Jul 2012
CompletionActual
Sep 2015
Results first posted
Apr 23, 2013
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00829166
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 26, 2009
Start date
Feb 2009
Primary completion
Jul 2012
Completion
Sep 2015
Results posted
Apr 23, 2013
Last update
Oct 31, 2016

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ado-Trastuzumab Emtansine

Start the discussion